Evidence map›Paper›PMID 25809828›Full record

Trial reportInternational journal of obesity (2005)2015

Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.

A Miccheli, G Capuani, F Marini, A Tomassini, G Praticò, S Ceccarelli, D Gnani, G Baviera, A Alisi, L Putignani and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of obesity (2005), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Pharmacometabolomics by NMR in Oncology: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

A MiccheliDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
G CapuaniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
F MariniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
A TomassiniDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
G PraticòDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
S CeccarelliLiver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
D GnaniLiver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
G BavieraFamily Pediatrician, Rome, Italy.
A Alisi1] Liver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy [2] Hepato-Metabolic Disease Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
L Putignani1] Parasitology Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy [2] Metagenomics Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
V Nobili1] Liver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy [2] Hepato-Metabolic Disease Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNowadays, non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in children. Our recent clinical trial demonstrated that dietary and VSL#3-based interventions may improve fatty liver by ultrasound and body mass index (BMI) after 4 months.

objectivesAs in this short-term trial, as in others, it is impracticable to monitor response to therapy or treatment by liver biopsy, we aimed to identify a panel of potential non-invasive metabolic biomarkers by a urinary metabolic profiling.

methodsUrine samples from a group of 31 pediatric NAFLD patients, enrolled in a VSL#3 clinical trial, were analyzed by high-resolution proton nuclear magnetic resonance spectroscopy in combination with analysis of variance-Simultaneous Component Analysis model and multivariate data analyses. Urinary metabolic profiles were interpreted in terms of clinical patient feature, treatment and chronology pattern correlations.

resultsVSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly at level of host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine), creatinine metabolism (methylguanidine) and secondarily at the level of gut microbial amino-acid metabolism (that is, 2-hydroxyisobutyrate from valine degradation). Furthermore, some of these metabolites correlated with clinical primary and secondary trial end points after VSL#3 treatment: tyrosine and the organic acid U4 positively with alanine aminotransferase (R=0.399, P=0.026) and BMI (R=0.36, P=0.045); BAIBA and tyrosine negatively with active glucagon-like-peptide 1 (R=-0.51, P=0.003; R=-0.41, P=0.021, respectively).

conclusionsVSL#3 treatment-dependent urinary metabotypes of NAFLD children may be considered as non-invasive effective biomarkers to evaluate the response to treatment.

Indexed as

Alanine TransaminaseAminoisobutyric AcidsBiomarkersBody Mass IndexChildDietary SupplementsDouble-Blind MethodFemaleHumansHydroxybutyratesLiverMagnetic Resonance SpectroscopyMaleMetabolomicsNon-alcoholic Fatty Liver DiseasePediatric Obesity2-hydroxyisobutyric acid3-aminoisobutyric acidAlanine TransaminaseAminoisobutyric AcidsBiomarkersHydroxybutyrates

Identifiers

PMID25809828
OpenAlexW2063096782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.